Maynard Um
-
-
-
-
-
-
-
RBC Capital on 4D Molecular Therapeutics (FDMT): 'Story Remains On Track for Late-Stage Execution in wAMD and Pipeline Growth'
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $16 at Leerink Partners
-
-
-
-
-
-
-
4D Molecular Therapeutics (FDMT) PT Lowered to $27 at Leerink Partners
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
-
-
-
-
Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
-
-
-
418,488 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

